Targeting known variants for cancer related genes

Fixed and custom panels for cost-effective sequencing and easier data analysis

Illumina offers a broad portfolio of cancer panels and cancer-focused products across multiple application areas. These products have been optimized with clinical cancer research in mind.

Achieve sequence-ready libraries from as little as 1 ng of high-quality input or 10 ng formalin-fixed paraffin-embedded (FFPE) sample using efficient, optimized assays and integrated sequencing and bioinformatics. Our comprehensive offering includes both fixed panels and custom options.

Cancer Panels for Targeted Sequencing

AmpliSeq for Illumina and our TruSight cancer panels offer several library preparation, sequencing, and data analysis options for cancer research. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. Illumina systems deliver industry-leading sequencing—in fact, more than 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*

Select your application area below to find out more about our product offerings for cancer research.

Exclusive Offer for TruSight Oncology 500

Purchase the TruSight Oncology 500 assay for the first time and receive an exclusive limited time offer.

Learn More
TruSight Oncology 500
Multisite Validation of Solid Tumor Panel

Multi-Site Analytical Validation of TruSight Tumor 15 (TST15) Determining Robustness and Concordance

Read Paper
New Views of Cancer Pathways in Pediatric Leukemia

Researchers are using the TruSight RNA Pan-Cancer Panel to understand the role of fusion genes in pediatric leukemia.

Read Article
Accurate Identification of Cancer Biomarkers

Dr Ravindra Kolhe and his team use TruSight Tumor 170 to study a wide number of variants associated with solid tumors.

Read Article
Comprehensive Genomic Profiling (CGP)

This NGS approach consolidates hundreds of cancer-related biomarkers, including different variant types, into a single assay. Explore the benefits and find out how it compares to other NGS methods.

Learn More About CGP

Scientist Pipetting
Transforming Diagnoses and Care for Acute Myeloid Leukemia
Transforming Diagnoses and Care for Acute Myeloid Leukemia

Illumina supports program to bring NGS technology to Latin America

Read Article
Using Genetic Testing to Advance Cancer Care
Using Genetic Testing to Advance Cancer Care

Australia-based XING Cancer Care is analyzing tumor DNA with the goal of improving cancer treatment.

Read Interview
The New Workflow: How Labs Will Benefit from TSO 500 Updates
The New Workflow: How Labs Will Benefit from TSO 500 Updates

Innovative enhancements streamline enablement of in-house comprehensive genomic profiling

Read Article
Image
Removing Cancer's Veil: TruSight Tumor 170

A new enrichment-based cancer research assay interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants.

View Video
Resources for Onboarding NGS
Resources for Onboarding NGS

View educational resources from recognized oncology experts and regulatory bodies about onboarding NGS.

View Resources
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up
Amplicon Sequencing
Amplicon Sequencing

Ultra-deep sequencing of PCR amplicons enables analysis of specific genomic regions of interest.

Learn More
Cancer Panels Demonstrate Value in Tumor Studies
Cancer Panels Demonstrate Value in Tumor Studies

Clinical researchers share how TruSight Tumor 170 and TruSight Oncology 500 can play an important role in tumor characterization.

Read Interview
References

*Data calculations on file. Illumina, Inc. 2017.